Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth?

Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth? editorial memo (2011) Vol. 4: 1–2 DOI 10.1007/s12254-011-0244-9 Printed in Austria © Springer-Verlag 2011 Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth? Mircea Dediu, MD, PhD M. Dediu Medical Oncology Department, Institute of Oncology “Alexandru Trestioreanu”, Bucharest, Romania Received 4 February 2011; accepted 10 February 2011 Maintenance therapy (MT) in non-small cell lung cancer [2, 3]. Some supporting data of this bias are emerging from (NSCLC) could be defi ned as continuation of an active treat- the IFCT-GFPC 0502 study [9]. Patients with advanced NSCLC ment until disease progression(PD) in patients who have were started on cisplatin/gemcitabine. Th e non-progressing demonstrated at least a non-progressing status following the patients following 4 cycles were randomized to either obser- fi rst-line chemotherapy (CT). First-line CT is limited to 4 cy- vation, continuous maintenance with gemcitabine, or switch cles. Although many arguments supporting MT are presented maintenance with erlotinib. Th e best results in terms of im- by Rotschild S et al. in this issue of memo [1], a lot of contro- proved progression free survival (PFS) were recorded in the versies are still surrounding this topic. gemcitabine continuation arm (HR = 0.55, p < 0.0001), while http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth?

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/maintenance-therapy-for-patients-with-advanced-non-small-cell-lung-I9pHO3W4Lk

References (21)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0244-9
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2011) Vol. 4: 1–2 DOI 10.1007/s12254-011-0244-9 Printed in Austria © Springer-Verlag 2011 Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth? Mircea Dediu, MD, PhD M. Dediu Medical Oncology Department, Institute of Oncology “Alexandru Trestioreanu”, Bucharest, Romania Received 4 February 2011; accepted 10 February 2011 Maintenance therapy (MT) in non-small cell lung cancer [2, 3]. Some supporting data of this bias are emerging from (NSCLC) could be defi ned as continuation of an active treat- the IFCT-GFPC 0502 study [9]. Patients with advanced NSCLC ment until disease progression(PD) in patients who have were started on cisplatin/gemcitabine. Th e non-progressing demonstrated at least a non-progressing status following the patients following 4 cycles were randomized to either obser- fi rst-line chemotherapy (CT). First-line CT is limited to 4 cy- vation, continuous maintenance with gemcitabine, or switch cles. Although many arguments supporting MT are presented maintenance with erlotinib. Th e best results in terms of im- by Rotschild S et al. in this issue of memo [1], a lot of contro- proved progression free survival (PFS) were recorded in the versies are still surrounding this topic. gemcitabine continuation arm (HR = 0.55, p < 0.0001), while

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Apr 21, 2011

There are no references for this article.